Retrospective comparison of bone marrow and granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells for allogeneic stem cell transplantation using HLA identical sibling donors in myelodysplastic syndromes
Autor: | Marc A. Boogaerts, Ronald Brand, Volker Runde, Jürgen Finke, Jan J. Cornelissen, Enric Carreras, Anja van Biezen, Eliane Gluckman, Andrea Bacigalupo, Antonio Pagliuca, Tapani Ruutu, Dietger Niederwieser, Philippe Guardiola, H. C. Schouten, Theo de Witte, Franco Locatelli |
---|---|
Přispěvatelé: | Hematology, Cardiology |
Rok vydání: | 2002 |
Předmět: |
Adult
Male medicine.medical_specialty Adolescent medicine.medical_treatment Immunology Bone Marrow Cells Hematopoietic stem cell transplantation Neutropenia Biochemistry Gastroenterology Nuclear Family Transplantation Immunology Internal medicine Granulocyte Colony-Stimulating Factor medicine Humans Child Survival analysis Retrospective Studies business.industry Histocompatibility Testing Myelodysplastic syndromes Hematopoietic Stem Cell Transplantation Cell Biology Hematology Middle Aged Hematopoietic Stem Cells medicine.disease Survival Analysis Hematopoietic Stem Cell Mobilization Granulocyte colony-stimulating factor Transplantation Transplantation Isogeneic Treatment Outcome medicine.anatomical_structure International Prognostic Scoring System Child Preschool Myelodysplastic Syndromes Female Bone marrow business Haematology |
Zdroj: | Blood, 99, 12, pp. 4370-8 Blood, 99, 4370-8 Blood, 99(2), 4370-4378. American Society of Hematology |
ISSN: | 1528-0020 0006-4971 |
Popis: | Item does not contain fulltext In this multicenter retrospective study, the outcomes of 234 patients with myelodysplastic syndrome (MDS) who underwent transplantation between 1995 and 1999 from HLA-identical siblings were analyzed according to the hematopoietic stem cell source used, that is, bone marrow (BM, n = 132) or granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells (PBPCs, n = 102). There were 69 cases of refractory anemia (RA), 86 RA with excess blasts (RAEB), 75 RAEB in transformation (RAEB-t), and 4 unclassified MDS at diagnosis. The International Prognostic Scoring System was intermediate-2 or high in 104 of the 158 available scores. Multivariate analyses focused on transplantation-related mortality (TRM), 2-year treatment failure incidence, and survival. Use of PBPCs reduced the median duration of neutropenia and thrombocytopenia by 4 and 12 days, respectively. The incidence of acute GVHD was similar whatever the graft type used. Chronic GVHD was more likely to have occurred with PBPCs (odds ratio [OR], 1.62; 95% confidence interval [CI], 0.87-3.02). Two-year TRM was significantly reduced with PBPCs (relative risk [RR], 0.33; 95% CI, 0.15-0.73; P |
Databáze: | OpenAIRE |
Externí odkaz: |